New combination drug joins domestic type 2 diabetes market

Published: 2012-08-27 06:59:00

Updated: 2012-08-27 06:59:00

Kombiglyze XR, a combined formulation of metformin and saxagliptin, has recently joined the arsenal of drugs available to treat type 2 diabetes, according to Bristol-Myers Squibb Korea and AstraZeneca Korea.

The drug is the first and only once-a-day metformin extended-release (XR) plus dipepti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK